よむ、つかう、まなぶ。
【参考資料２－３】抗微生物薬適正使用の手引き 第四版（案）薬剤耐性菌感染症の抗菌薬適正使用編 (56 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_64503.html |
| 出典情報 | 厚生科学審議会 感染症部会（第99回 10／21）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
1
2
3
162. Chen H, et al. Efficacy of sulbactam for the treatment of Acinetobacter baumannii
complex infection: A systematic review and meta-analysis. J Infect Chemother. 2017.
23(5):278-285.
4
5
163. Jaruratanasirikul S, et al. Pharmacodynamics modeling to optimize dosage regimens of
sulbactam. Antimicrob Agents Chemother. 2013. 57(7):3441-3444.
6
7
8
9
164. Jaruratanasirikul S, et al. Population Pharmacokinetics and Pharmacodynamics
Modeling To Optimize Dosage Regimens of Sulbactam in Critically Ill Patients with
Severe Sepsis Caused by Acinetobacter baumannii. Antimicrob Agents Chemother.
2016. 60(12):7236-7244.
10
11
165. Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.
Clin Microbiol Rev. 2012. 25(1):2-41.
12
13
166. Brooke JS. Advances in the Microbiology of Stenotrophomonas maltophilia. Clin
Microbiol Rev. 2021. 34(3):e0003019.
14
15
167. Safdar A, et al. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial
pathogen in patients with cancer. Clin Infect Dis. 2007. 45(12):1602-1609.
16
17
18
168. Kim SH, et al. Pathogenic significance of hemorrhagic pneumonia in hematologic
malignancy patients with Stenotrophomonas maltophilia bacteremia: clinical and
microbiological analysis. Eur J Clin Microbiol Infect Dis. 2019. 38(2):285-295.
19
20
21
169. Araoka H, et al. Rapidly progressive fatal hemorrhagic pneumonia caused by
Stenotrophomonas maltophilia in hematologic malignancy. Transpl Infect Dis. 2012.
14(4):355-363.
22
23
170. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for
interpretation of MICs and zone diameters. Version 15.0, 2025. https://www.eucast.org.
24
25
171. 石井良和. 薬剤感受性試験とブレイクポイント, その問題点と今後の展望. 日本化学療法
学会雑誌. 2011. 59(5):454-9.
26
27
172. Perez F, et al. Antibiotic-resistant gram-negative bacterial infections in patients with
cancer. Clin Infect Dis. 2014. 59 Suppl 5:S335-9.
28
29
173. Cairo J, et al. Predictors of catheter-related gram-negative bacilli bacteraemia among
cancer patients. Clin Microbiol Infect. 2011. 17(11):1711-1716.
30
31
174. Mojica MF, et al. Clinical challenges treating Stenotrophomonas maltophilia infections:
an update. JAC Antimicrob Resist. 2022. 4(3):dlac040.
32
33
175. Tamma PD, et al. Association of Adverse Events With Antibiotic Use in Hospitalized
Patients. JAMA Intern Med. 2017. 177(9):1308-1315.
34
35
36
176. Cho SY, et al. Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole
for treating Stenotrophomonas maltophilia bacteremia? Antimicrob Agents Chemother.
2014. 58(1):581-3.
37
38
39
40
177. Wei C, et al. Evaluation of Trimethoprim/Sulfamethoxazole (SXT), Minocycline,
Tigecycline, Moxifloxacin, and Ceftazidime Alone and in Combinations for SXTSusceptible and SXT-Resistant Stenotrophomonas maltophilia by In Vitro Time-Kill
Experiments. PLoS One. 2016. 11(3):e0152132.
41
42
43
178. Zelenitsky SA, et al. Antibiotic combinations significantly more active than monotherapy
in an in vitro infection model of Stenotrophomonas maltophilia. Diagn Microbiol Infect
Dis. 2005. 51(1):39-43.
56
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
1
2
3
162. Chen H, et al. Efficacy of sulbactam for the treatment of Acinetobacter baumannii
complex infection: A systematic review and meta-analysis. J Infect Chemother. 2017.
23(5):278-285.
4
5
163. Jaruratanasirikul S, et al. Pharmacodynamics modeling to optimize dosage regimens of
sulbactam. Antimicrob Agents Chemother. 2013. 57(7):3441-3444.
6
7
8
9
164. Jaruratanasirikul S, et al. Population Pharmacokinetics and Pharmacodynamics
Modeling To Optimize Dosage Regimens of Sulbactam in Critically Ill Patients with
Severe Sepsis Caused by Acinetobacter baumannii. Antimicrob Agents Chemother.
2016. 60(12):7236-7244.
10
11
165. Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.
Clin Microbiol Rev. 2012. 25(1):2-41.
12
13
166. Brooke JS. Advances in the Microbiology of Stenotrophomonas maltophilia. Clin
Microbiol Rev. 2021. 34(3):e0003019.
14
15
167. Safdar A, et al. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial
pathogen in patients with cancer. Clin Infect Dis. 2007. 45(12):1602-1609.
16
17
18
168. Kim SH, et al. Pathogenic significance of hemorrhagic pneumonia in hematologic
malignancy patients with Stenotrophomonas maltophilia bacteremia: clinical and
microbiological analysis. Eur J Clin Microbiol Infect Dis. 2019. 38(2):285-295.
19
20
21
169. Araoka H, et al. Rapidly progressive fatal hemorrhagic pneumonia caused by
Stenotrophomonas maltophilia in hematologic malignancy. Transpl Infect Dis. 2012.
14(4):355-363.
22
23
170. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for
interpretation of MICs and zone diameters. Version 15.0, 2025. https://www.eucast.org.
24
25
171. 石井良和. 薬剤感受性試験とブレイクポイント, その問題点と今後の展望. 日本化学療法
学会雑誌. 2011. 59(5):454-9.
26
27
172. Perez F, et al. Antibiotic-resistant gram-negative bacterial infections in patients with
cancer. Clin Infect Dis. 2014. 59 Suppl 5:S335-9.
28
29
173. Cairo J, et al. Predictors of catheter-related gram-negative bacilli bacteraemia among
cancer patients. Clin Microbiol Infect. 2011. 17(11):1711-1716.
30
31
174. Mojica MF, et al. Clinical challenges treating Stenotrophomonas maltophilia infections:
an update. JAC Antimicrob Resist. 2022. 4(3):dlac040.
32
33
175. Tamma PD, et al. Association of Adverse Events With Antibiotic Use in Hospitalized
Patients. JAMA Intern Med. 2017. 177(9):1308-1315.
34
35
36
176. Cho SY, et al. Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole
for treating Stenotrophomonas maltophilia bacteremia? Antimicrob Agents Chemother.
2014. 58(1):581-3.
37
38
39
40
177. Wei C, et al. Evaluation of Trimethoprim/Sulfamethoxazole (SXT), Minocycline,
Tigecycline, Moxifloxacin, and Ceftazidime Alone and in Combinations for SXTSusceptible and SXT-Resistant Stenotrophomonas maltophilia by In Vitro Time-Kill
Experiments. PLoS One. 2016. 11(3):e0152132.
41
42
43
178. Zelenitsky SA, et al. Antibiotic combinations significantly more active than monotherapy
in an in vitro infection model of Stenotrophomonas maltophilia. Diagn Microbiol Infect
Dis. 2005. 51(1):39-43.
56